Use of durvalumab consolidation therapy in all eligible patients with NSCLC was deemed cost-effective, despite its incremental budgetary consequence of $768 million in year 1.
from Latest articles from Cancer Therapy Advisor News https://ift.tt/2Sdu8I2
from Latest articles from Cancer Therapy Advisor News https://ift.tt/2Sdu8I2